Journal of Molecular Medicine

, Volume 83, Issue 11, pp 917–926 | Cite as

Clinical significance of EGFR amplification and the aberrant EGFRvIII transcript in conventionally treated astrocytic gliomas

  • Lu Liu
  • L. Magnus Bäcklund
  • Bo R. Nilsson
  • Dan Grandér
  • Koichi Ichimura
  • Helena M. Goike
  • V. Peter CollinsEmail author
Original Article


The aim of this study was to evaluate the clinical value of assessing epidermal growth factor receptor (EGFR) amplification and the common 5′ rearrangement of EGFR resulting in the EGFRvIII transcript in astrocytic gliomas. Data from 221 tumours were correlated with patient survival. The majority of previous studies evaluated amplification alone and provided contradictory results. Amplification was analysed by a densitometry of Southern blot analysis or quantitative polymerase chain reaction (PCR). EGFR transcripts were examined by reverse transcription PCR and subsequent sequencing. A ribonuclease (RNase) protection assay was carried out on a subgroup to confirm PCR results. Amplification of EGFR was found in 41% (65/160) of glioblastomas (GBs) and 10% (4/41) of anaplastic astrocytomas (AAs). The EGFRvIII rearrangement was identified in 54% (35/65) of GBs and 75% (3/4) of AAs with amplification, as well as in 8% (8/95) of GBs and 5% (2/37) of AAs without amplification (confirmed by RNase protection assay). There were no abnormalities of the EFGR or its transcript in grade II astrocytoma (AII). We found no significant association between EGFR amplification or rearrangement, and age or survival in the 160 GB patients. We noted a tendency towards decreased survival with any EGFR abnormality in the 41 patients with AAs. This was most marked in the five cases with the EGFRvIII transcript (p=0.069), but these were significantly older than those without (p=0.023). No abnormalities of EGFR were identified in AII patients. We conclude that neither EGFR amplification nor the presence of the EGFRvIII transcript predicts patient outcome in conventionally treated GBs. However, in AAs, although uncommon, EGFR aberrations appear to be associated with shorter survival.


EGFRvIII Survival Transcript Glioblastoma 



We thank the Departments of Neurosurgery and Pathology at the Karolinska University Hospital, Sahlgrenska University Hospital, and many other hospitals in Sweden that helped us obtain follow-up data.


  1. 1.
    Schlessinger J (2000) Cell signaling by receptor tyrosine kinases. Cell 103:211–225CrossRefPubMedGoogle Scholar
  2. 2.
    Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2:127–137CrossRefPubMedGoogle Scholar
  3. 3.
    Ekstrand AJ, Sugawa N, James CD, Collins VP (1992) Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails. Proc Natl Acad Sci U S A 89:4309–4313PubMedGoogle Scholar
  4. 4.
    Moscatello DK, Holgado-Madruga M, Godwin AK, Ramirez G, Gunn G, Zoltick PW, Biegel JA, Hayes RL, Wong AJ (1995) Frequent expression of a mutant epidermal growth factor receptor in multiple human tumours. Cancer Res 55:5536–5539PubMedGoogle Scholar
  5. 5.
    Salomon DS, Brandt R, Ciardiello F, Normanno N (1995) Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19:183–232PubMedGoogle Scholar
  6. 6.
    Sugawa N, Ekstrand AJ, James CD, Collins VP (1990) Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proc Natl Acad Sci U S A 87:8602–8606PubMedGoogle Scholar
  7. 7.
    Wong AJ, Ruppert JM, Bigner SH, Grzeschik CH, Humphrey PA, Bigner DS, Vogelstein B (1992) Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci U S A 89:2965–2969PubMedGoogle Scholar
  8. 8.
    Humphrey PA, Wong AJ, Vogelstein B, Zalutsky MR, Fuller GN, Archer GE, Friedman HS, Kwatra MM, Bigner SH, Bigner DD (1990) Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma. Proc Natl Acad Sci U S A 87:4207–4211PubMedGoogle Scholar
  9. 9.
    Backlund LM, Nilsson BR, Goike HM, Schmidt EE, Liu L, Ichimura K, Collins VP (2003) Short postoperative survival for glioblastoma patients with a dysfunctional Rb1 pathway in combination with no wild-type PTEN. Clin Cancer Res 9:4151–4158PubMedGoogle Scholar
  10. 10.
    Galanis E, Buckner J, Kimmel D, Jenkins R, Alderete B, O’Fallon J, Wang CH, Scheithauer BW, James CD (1998) Gene amplification as a prognostic factor in primary and secondary high-grade malignant gliomas. Int J Oncol 13:717–724PubMedGoogle Scholar
  11. 11.
    Tohma Y, Gratas C, Biernat W, Peraud A, Fukuda M, Yonekawa Y, Kleihues P, Ohgaki H (1998) PTEN (MMAC1) mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas. J Neuropathol Exp Neurol 57:684–689PubMedGoogle Scholar
  12. 12.
    Olson JJ, Barnett D, Yang J, Assietti R, Cotsonis G, James CD (1998) Gene amplification as a prognostic factor in primary brain tumours. Clin Cancer Res 4:215–222PubMedGoogle Scholar
  13. 13.
    Smith JS, Tachibana I, Passe SM, Huntley BK, Borell TJ, Iturria N, O’Fallon JR, Schaefer PL, Scheithauer BW, James CD, Buckner JC, Jenkins RB (2001) PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst 93:1246–1256CrossRefPubMedGoogle Scholar
  14. 14.
    Kleihues P, Cavanee WK (2000) WHO classification of tumours, pathology and genetics of the nervous system. IARC Press, LyonGoogle Scholar
  15. 15.
    Ekstrand AJ, James CD, Cavenee WK, Seliger B, Pettersson RF, Collins VP (1991) Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res 51:2164–2172PubMedGoogle Scholar
  16. 16.
    Liu L, Ichimura K, Pettersson EH, Collins VP (1998) Chromosome 7 rearrangements in glioblastomas; loci adjacent to EGFR are independently amplified. J Neuropathol Exp Neurol 57:1138–1145PubMedGoogle Scholar
  17. 17.
    Frederick L, Wang XY, Eley G, James CD (2000) Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res 60:1383–1387PubMedGoogle Scholar
  18. 18.
    Shinojima N, Tada K, Shiraishi S, Kamiryo T, Kochi M, Nakamura H, Makino K, Saya H, Hirano H, Kuratsu J, Oka K, Ishimaru Y, Ushio Y (2003) Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res 63:6962–6970PubMedGoogle Scholar
  19. 19.
    Ohgaki H, Dessen P, Jourde B, Horstmann S, Nishikawa T, Di Patre PL, Burkhard C, Schuler D, Probst-Hensch NM, Maiorka PC, Baeza N, Pisani P, Yonekawa Y, Yasargil MG, Lutolf UM, Kleihues P (2004) Genetic pathways to glioblastoma: a population-based study. Cancer Res 64:6892–6899PubMedGoogle Scholar
  20. 20.
    Huncharek M, Kupelnick B (2000) Epidermal growth factor receptor gene amplification as a prognostic marker in glioblastoma multiforme: results of a meta-analysis. Oncol Res 12:107–112PubMedGoogle Scholar
  21. 21.
    Ichimura K, Schmidt EE, Goike HM, Collins VP (1996) Human glioblastomas with no alterations of the CDKN2A (p16INK4A, MTS1) and CDK4 genes have frequent mutations of the retinoblastoma gene. Oncogene 13:1065–1072PubMedGoogle Scholar
  22. 22.
    Ichimura K, Schmidt EE, Yamaguchi N, James CD, Collins VP (1994) A common region of homozygous deletion in malignant human gliomas lies between the IFN alpha/omega gene cluster and the D9S171 locus. Cancer Res 54:3127–3130PubMedGoogle Scholar
  23. 23.
    Gehan EA (1965) A generalized two-sample Wilcoxon test for doubly censored data. Biometrika 52:650–653PubMedGoogle Scholar
  24. 24.
    Ekstrand AJ, Longo N, Hamid ML, Olson JJ, Liu L, Collins VP, James CD (1994) Functional characterization of an EGF receptor with a truncated extracellular domain expressed in glioblastomas with EGFR gene amplification. Oncogene 9:2313–2320PubMedGoogle Scholar
  25. 25.
    Aldape KD, Ballman K, Furth A, Buckner JC, Giannini C, Burger PC, Scheithauer BW, Jenkins RB, James CD (2004) Immunohistochemical detection of EGFRvIII in high malignancy grade astrocytomas and evaluation of prognostic significance. J Neuropathol Exp Neurol 63:700–707PubMedGoogle Scholar
  26. 26.
    Baselga J (2001) Targeting the epidermal growth factor receptor: a clinical reality. J Clin Oncol 19:41S–44SPubMedGoogle Scholar
  27. 27.
    Jungbluth AA, Stockert E, Huang HJ, Collins VP, Coplan K, Iversen K, Kolb D, Johns TJ, Scott AM, Gullick WJ, Ritter G, Cohen L, Scanlan MJ, Cavenee WK, Old LJ, Cavanee WK (2003) A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor. Proc Natl Acad Sci U S A 100:639–644PubMedGoogle Scholar
  28. 28.
    Masui H, Kawamoto T, Sato JD, Wolf B, Sato G, Mendelsohn J (1984) Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 44:1002–1007PubMedGoogle Scholar
  29. 29.
    Sampson JH, Crotty LE, Lee S, Archer GE, Ashley DM, Wikstrand CJ, Hale LP, Small C, Dranoff G, Friedman AH, Friedman HS, Bigner DD (2000) Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors. Proc Natl Acad Sci U S A 97:7503–7508PubMedGoogle Scholar
  30. 30.
    Quang TS, Brady LW (2004) Radioimmunotherapy as a novel treatment regimen: 125I-labeled monoclonal antibody 425 in the treatment of high-grade brain gliomas. Int J Radiat Oncol Biol Phys 58:972–975PubMedGoogle Scholar
  31. 31.
    Han Y, Caday CG, Umezawa K, Nanda A (1997) Preferential inhibition of glioblastoma cells with wild-type epidermal growth factor receptors by a novel tyrosine kinase inhibitor ethyl-2,5-dihydroxycinnamate. Oncol Res 9:581–587PubMedGoogle Scholar
  32. 32.
    Han Y, Caday CG, Nanda A, Cavenee WK, Huang HJ (1996) Tyrphostin AG 1478 preferentially inhibits human glioma cells expressing truncated rather than wild-type epidermal growth factor receptors. Cancer Res 56:3859–3861PubMedGoogle Scholar
  33. 33.
    Phillips PC, Levow C, Catterall M, Colvin OM, Pastan I, Brem H (1994) Transforming growth factor-alpha–Pseudomonas exotoxin fusion protein (TGF-alpha–PE38) treatment of subcutaneous and intracranial human glioma and medulloblastoma xenografts in athymic mice. Cancer Res 54:1008–1015PubMedGoogle Scholar
  34. 34.
    Brady LW, Miyamoto C, Woo DV, Rackover M, Emrich J, Bender H, Dadparvar S, Steplewski Z, Koprowski H, Black P et al (1992) Malignant astrocytomas treated with iodine-125 labelled monoclonal antibody 425 against epidermal growth factor receptor: a phase II trial. Int J Radiat Oncol Biol Phys 22:225–230PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2005

Authors and Affiliations

  • Lu Liu
    • 1
  • L. Magnus Bäcklund
    • 2
  • Bo R. Nilsson
    • 2
  • Dan Grandér
    • 2
  • Koichi Ichimura
    • 1
  • Helena M. Goike
    • 2
  • V. Peter Collins
    • 1
    Email author
  1. 1.Division of Molecular Histopathology, Department of Pathology, Addenbrooke’s HospitalUniversity of CambridgeCambridgeUK
  2. 2.Department of Oncology–PathologyKarolinska University HospitalStockholmSweden

Personalised recommendations